2017 American Transplant Congress » Poster Session A: Clinical Science: Kidney Immunosuppression: Desensitization

5:30pm-7:30pm

Assessing the Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients After Desensitization (Des) 2 Years Post Implementation.

A. Vo,¹ S. Williamson,¹ K. Myers,¹ E. Huang,¹ J. Choi,¹ X. Zhang,² A. Peng,¹ R. Najjar,¹ S. Jordan.¹

5:30pm-7:30pm

Avoidance or Reduction of Rituximab Might Improve Clinical Outcomes in ABO-Incompatible Renal Transplantation: Advantages and Disadvantages of Rituximab.

M. Okada,¹ Y. Watarai,¹ K. Iwasaki,² K. Murotani,³ T. Hiramitsu,¹ M. Tsujita,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²

5:30pm-7:30pm

Comparing Outcomes of ABO Incompatible to DSA Positive/CDC-AHG Negative Kidney Transplantation.

T. Kitrungphaiboon,¹ N. Townamchai,¹ D. Saengpanit,¹ K. Iampenkhae,² K. Jutivorakool,¹ Y. Avihingsanon,¹ K. Praditpornsilpa.¹

5:30pm-7:30pm

Complement Markers in Immunoadsorption Combined with Membrane Filtration.

P. Malvezzi,¹ F. Defendi,² F. Eskandary,³ T. Jouve,¹ L. Rostaing,¹ C. Dumestre-Perard,² G. Böhmig.³

5:30pm-7:30pm

Effect of Induction Therapy in ABO Incompatible Living-Donor Kidney Transplantation: A Single Center Experience.

L. Lanfranco, L. Esposito, A. Del Bello, O. Cointault, A. Allal, L. Rostaing, N. Kamar.

5:30pm-7:30pm

Factors Affecting Desensitization Outcome.

A. Zachary,¹ R. Montgomery,² M. Leffell.¹

5:30pm-7:30pm

Outcome of ABO-Incompatible Kidney Transplantation After Stratified Desensitization.

K. Nanmoku, A. Kurosawa, T. Kubo, T. Shinzato, T. Shimizu, T. Kimura, T. Yagisawa.

5:30pm-7:30pm

Outcome of Living-Donor Kidney Transplantation in Cross-Match-Positive Recipients at a Single Center.

D. Okada,¹ M. Okumi,¹ K. Unagami,² T. Shimizu,¹ H. Ishida,¹ K. Tanabe.¹

5:30pm-7:30pm

Outcomes of 100 ABO Incompatible Kidney Transplants: A Single US Center Experience.

S. Sethi, A. Vo, E. Huang, L. Varanasi, J. Choi, A. Peng, R. Najjar, S. Jordan.

5:30pm-7:30pm

Percentage of CD19⁺ B Cells as a Predictor of Acute Antibody-Mediated Rejection After Administration of Rituximab in ABO-Incompatible Kidney Transplantation.

T. Hirose, D. Iwami, K. Hotta, H. Sasaki, H. Higuchi, N. Shinohara.

5:30pm-7:30pm

Presence of Complement Activating Donor Specific Antibodies Is Associated with Poor Renal Allograft Survival: Two Centre Retrospective Study.

A. Babu,^1,4,5 O. Shaw,² L. Howe,² N. Kessaris,³ A. Dorling,³ N. Mamode,³ R. Vaughan,² N. Krishnan,⁵ R. Higgins,⁵ D. MItchell,¹ D. Briggs,⁴ S. Daga.^1,5,6

5:30pm-7:30pm

Prognostic Tools to Choose Candidates for Successful Desensitization.

D. Pinelli,¹ A. Zachary,² J. Friedewald,¹ M. Leffell,² D. Lucas,² R. Montgomery,² A. Tambur.¹

5:30pm-7:30pm

Successful Launch of an ABO-Incompatible Kidney Transplantation Program to Overcome the Shortage of Compatible Living Donors: Experience at a Single Center.

S. Song,¹ J. Lee,¹ J. Lee,¹ S.-K. Kwon,¹ B. Kim,^2,3 J. Lee,¹ Y. Kim,^1,3 M. Kim,^1,3 S. Kim,^1,3 K. Huh.^1,3

5:30pm-7:30pm

The Impact of Belatacept on Anti-HLA Antibodies of Highly Sensitized Kidney Transplant Recipients.

R. Parsons, H. Decker, T. Pearson, C. Larsen, R. Bray, H. Gebel.

5:30pm-7:30pm

Three Year Outcomes Following Positive Crossmatch Renal Transplantation Despite Failure to Convert to Negative Flow Crossmatch After Desensitization.

S. Patel,¹ J. Benken,¹ S. Akkina,³ P. West-Thielke,² J. Thielke,¹ M. Campara,¹ J. Oberholzer,² E. Benedetti.²

5:30pm-7:30pm

Update of a Placebo-Controlled Trial of C1 Esterase Inhibitor for Prevention of Antibody Mediated Rejection (ABMR) in Highly-HLA Sensitized Patients.

A. Vo, J. Choi, A. Peng, K. Lim, L. Varanasi, R. Najjar, E. Huang, D. Puliyanda, S. Jordan.